IntelGenx Technologies Corp.
IGX
Kedudukan dalam Saham
#28120
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Harga Saham
$0.17446996
Disegerakkan terakhir: 2024-06-11
Modal Pasaran
$26.97M
Perubahan (1 hari)
-0.57%
Perubahan (1 tahun)
2.63%
Negara
CA
Perdagangan IntelGenx Technologies Corp. (IGX)
Kategori
Healthcare
Nisbah P/E bagi IntelGenx Technologies Corp. (IGX)
Nisbah P/E pada October 2026 TTM: -2.99
Menurut laporan kewangan dan harga saham terkini IntelGenx Technologies Corp., nisbah P/E semasa (TTM) ialah -2.99. Pada akhir 2022, syarikat mempunyai nisbah P/E sebanyak -2.72.
Sejarah nisbah P/E bagi IntelGenx Technologies Corp. dari 2003 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | -2.99 | 23.17% |
| 2023 | -2.43 | -10.53% |
| 2022 | -2.72 | -48.72% |
| 2021 | -5.30 | 83.07% |
| 2020 | -2.89 | -21.89% |
| 2019 | -3.70 | -6.46% |
| 2018 | -3.96 | -76.88% |
| 2017 | -17.13 | -59.48% |
| 2016 | -42.28 | -265.23% |
| 2015 | 25.59 | -235.98% |
| 2014 | -18.82 | 1.94% |
| 2013 | -18.46 | 28.72% |
| 2012 | -14.34 | 48.88% |
| 2011 | -9.63 | 141.19% |
| 2010 | -3.99 | -49.04% |
| 2009 | -7.84 | 86.48% |
| 2008 | -4.20 | -63.95% |
| 2007 | -11.66 | -9.24% |
| 2006 | -12.85 | -98.14% |
| 2005 | -691.69 | 416.60% |
| 2004 | -133.89 | -98.62% |
| 2003 | -9.72K | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -1,061.64% |
US
|
|
| -28.36 | 847.49% |
US
|
|
| -24.57 | 720.81% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -1,113.36% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.